Ernexa Therapeutics Inc.
ERNA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ERNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ERNA
Ernexa Therapeutics Inc. (ERNA) is a preclinical-stage biotechnology company developing engineered mesenchymal stem cell (iMSC) therapies for inflammatory and autoimmune diseases, with lead candidate ERNA-101 targeting graft-versus-host disease and ERNA-201 for autoimmune disorders.
Key risk: Preclinical stage, no approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Ernexa Therapeutics Inc. (ERNA) is a preclinical-stage biotechnology company developing engineered mesenchymal stem cell (iMSC) therapies for inflammatory and autoimmune diseases, with lead candidate ERNA-101 targeting graft-versus-host disease and ERNA-201 for autoimmune disorders.
- Ernexa is developing two iMSC programs: ERNA-101 for graft-versus-host disease and ERNA-201 for autoimmune disorders like rheumatoid arthritis [sec_mda · as of 2026-08-06].
- The company had a successful pre-IND meeting with the FDA in Q4 2025 and expects to submit an IND and enter a Phase I investigator-sponsored trial in the second half of 2026 [sec_mda · as of 2026-08-06].
- As of June 30, 2026, Ernexa reported cash & equivalents of $5.0M, net income of -$4.0M, and shareholders' equity of $2.4M [sec].
- The company has not been profitable since inception and may never achieve profitability [sec_mda · as of 2026-03-13].
- Ernexa has raised capital through sales of common stock, warrants, and convertible notes to fund operations [sec_mda · as of 2026-03-13].
What works
- Successful pre-IND meeting with the FDA in Q4 2025 indicates regulatory alignment on the development approach for ERNA-101 [sec_mda · as of 2026-08-06].
- iMSCs have intrinsic homing ability to inflamed tissue and can dampen inflammation through multiple mediators, providing a biological rationale for the platform [sec_mda · as of 2026-08-06].
- The company has two distinct programs (ERNA-101 and ERNA-201) targeting different indications, diversifying its pipeline [sec_mda · as of 2026-08-06].
What to weigh
- Ernexa is a preclinical-stage company with no approved products or revenue from product sales [sec_mda · as of 2026-03-13].
- Cash & equivalents of $5.0M as of June 30, 2026, may be insufficient to fund operations through key milestones without additional financing [sec].
- The company has a history of net losses and an accumulated deficit, with no guarantee of future profitability [sec_mda · as of 2026-03-13].
- Clinical development may be delayed or prevented by FDA clinical holds, negative study results, or other regulatory hurdles [sec_mda · as of 2026-03-13].
From the filings
Quoted directly from source documents.
Successful pre-IND meeting with FDA in Q4 2025
“During the fourth quarter of 2025, we had a successful pre-Investigational New Drug ("IND") meeting with the Food and Drug Administration ("FDA"), which resulted in regulatory alignment with our development approach.”
SEC MD&A · August 6, 2026
Expected IND submission and Phase I trial timeline
“We expect to complete the Investigational New Drug ("IND") enabling studies and IND submission in 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the second half of 2026.”
SEC MD&A · August 6, 2026
Company has not been profitable since inception
“We have not been profitable since we commenced operations and may never achieve profitability.”
SEC MD&A · March 13, 2026
Risks & what to watch (4)›
Key risks
- Preclinical stage, no approved products — Ernexa has no products approved for commercial sale and no revenue from product sales [sec_mda · as of 2026-03-13].
- Limited cash runway — Cash & equivalents of $5.0M as of June 30, 2026, may not be sufficient to fund operations through expected milestones [sec].
- Clinical development delays — Clinical studies may be delayed or prevented by FDA clinical holds, negative results, or regulatory issues [sec_mda · as of 2026-03-13].
- History of losses, going concern risk — The company has incurred net losses since inception and may need to liquidate assets if unable to continue as a going concern [sec_mda · as of 2026-03-13].
What to watch
- Completion of IND-enabling studies and IND submission in 2026 [sec_mda · as of 2026-08-06].
- Initiation of Phase I investigator-sponsored clinical trial for ERNA-101 in the second half of 2026 [sec_mda · as of 2026-08-06].
- Any updates on ERNA-201 preclinical development for autoimmune disorders [sec_mda · as of 2026-08-06].
- Future financing events or capital raises to extend cash runway [sec_mda · as of 2026-03-13].
Sources: SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run Ernexa Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ernexa Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.8 months
D/E 0.97 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of Apr 28, 2026- % of float
- 1.1%
- Days to cover
- 0.2
- Shares short
- 201,143
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ERNA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ernexa Therapeutics Inc.?
Ernexa Therapeutics Inc. (ERNA) is a preclinical-stage biotechnology company developing engineered mesenchymal stem cell (iMSC) therapies for inflammatory and autoimmune diseases, with lead candidate ERNA-101 targeting graft-versus-host disease and ERNA-201 for autoimmune disorders.
Who is the CEO of Ernexa Therapeutics Inc.?
Mr. Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc. (ERNA).
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. (ERNA) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.